Top-Rated StocksTop-RatedNASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $21.94 +0.90 (+4.28%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$21.23▼$22.2050-Day Range$15.11▼$23.8252-Week Range$4.22▼$24.38Volume590,599 shsAverage Volume984,924 shsMarket Capitalization$1.41 billionP/E RatioN/ADividend YieldN/APrice Target$25.82 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Nurix Therapeutics alerts: Email Address Nurix Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside17.7% Upside$25.82 Price TargetShort InterestBearish13.72% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.92Based on 5 Articles This WeekInsider TradingSelling Shares$271,888 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.78) to ($2.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.11 out of 5 starsMedical Sector810th out of 936 stocksPharmaceutical Preparations Industry376th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNurix Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nurix Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.72% of the outstanding shares of Nurix Therapeutics have been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 9.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRIX. Previous Next 2.7 News and Social Media Coverage News SentimentNurix Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Nurix Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $271,888.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Nurix Therapeutics is held by insiders.Read more about Nurix Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.78) to ($2.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -7.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -7.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nurix Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About Nurix Therapeutics Stock (NASDAQ:NRIX)Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Read More NRIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRIX Stock News HeadlinesJuly 2, 2024 | insidertrades.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Christine Ring Sells 5,760 SharesJuly 23 at 1:10 AM | americanbankingnews.comBrokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) PT at $25.82July 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.July 16, 2024 | americanbankingnews.comNurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $31.00 at BarclaysJuly 16, 2024 | americanbankingnews.comNurix Therapeutics (NASDAQ:NRIX) Given New $34.00 Price Target at JPMorgan Chase & Co.July 11, 2024 | globenewswire.comNurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateJune 19, 2024 | seekingalpha.comNurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull CaseMay 29, 2024 | finance.yahoo.comNurix Therapeutics to Participate in the Jefferies Global Healthcare ConferenceJuly 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.May 28, 2024 | msn.comNurix Therapeutics appoints Paula O’Connor as chief medical officerMay 28, 2024 | globenewswire.comNurix Therapeutics Appoints Paula G. O'Connor, M.D.May 20, 2024 | marketwatch.comNurix Therapeutics Names Julia Gregory As New ChairMay 20, 2024 | globenewswire.comNurix Therapeutics Announces Board Chair TransitionMay 19, 2024 | finance.yahoo.comNurix Therapeutics, Inc. (NRIX)May 16, 2024 | markets.businessinsider.comNurix Therapeutics Gains Buy Rating Amid Strong Clinical Advances for CLL Drug NX-5948May 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)May 14, 2024 | msn.comStephens & Co. Initiates Coverage of Nurix Therapeutics (NRIX) with Overweight RecommendationMay 14, 2024 | finance.yahoo.comNurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)See More Headlines Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/11/2024Today7/26/2024Next Earnings (Estimated)10/10/2024Fiscal Year End11/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NRIX CUSIPN/A CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Stock Price Target$25.82 High Stock Price Target$35.00 Low Stock Price Target$10.00 Potential Upside/Downside+16.7%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,950,000.00 Net Margins-264.84% Pretax Margin-264.55% Return on Equity-67.78% Return on Assets-44.37% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.57 Sales & Book Value Annual Sales$76.99 million Price / Sales18.51 Cash FlowN/A Price / Cash FlowN/A Book Value$5.76 per share Price / Book3.84Miscellaneous Outstanding Shares64,410,000Free Float45,612,000Market Cap$1.42 billion OptionableOptionable Beta2.22 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Arthur T. Sands M.D. (Age 62)Ph.D., CEO, President & Director Comp: $986.32kMr. Johannes Van Houte (Age 58)Chief Financial Officer Comp: $681.98kDr. Gwenn M. Hansen Ph.D. (Age 53)Chief Scientific Officer Comp: $702.75kDr. John Kuriyan Ph.D.Founder & Member of Scientific Advisory BoardMr. Michael Rapé Ph.D.Founder & Member of Scientific Advisory BoardDr. Arthur Weiss M.D.Ph.D., Founder & Member of Scientific Advisory BoardRita KwongSenior Accounting ManagerDr. Christine Ring J.D. (Age 59)Ph.D., Chief Legal Officer, Secretary & Chief Compliance Officer Comp: $595.83kMr. Eric C. Schlezinger J.D. (Age 57)Chief People Officer Dr. Jason Kantor Ph.D.Chief Business OfficerMore ExecutivesKey CompetitorsPraxis Precision MedicinesNASDAQ:PRAXCOMPASS PathwaysNASDAQ:CMPSLigand PharmaceuticalsNASDAQ:LGNDPMV PharmaceuticalsNASDAQ:PMVPArcellxNASDAQ:ACLXView All CompetitorsInsiders & InstitutionsARK Investment Management LLCSold 312,006 shares on 7/26/2024Ownership: 3.607%Bank of New York Mellon CorpBought 49,918 shares on 7/26/2024Ownership: 0.325%SG Americas Securities LLCBought 81,005 shares on 7/12/2024Ownership: 0.210%GAMMA Investing LLCBought 3,424 shares on 7/2/2024Ownership: 0.009%Christine RingSold 5,760 sharesTotal: $119,865.60 ($20.81/share)View All Insider TransactionsView All Institutional Transactions NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $10.32 at the beginning of 2024. Since then, NRIX stock has increased by 112.6% and is now trading at $21.94. View the best growth stocks for 2024 here. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) released its quarterly earnings data on Thursday, July, 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.08. The company had revenue of $12.09 million for the quarter, compared to analyst estimates of $19.35 million. Nurix Therapeutics had a negative net margin of 264.84% and a negative trailing twelve-month return on equity of 67.78%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Top institutional investors of Nurix Therapeutics include ARK Investment Management LLC (3.61%), Bank of New York Mellon Corp (0.32%), SG Americas Securities LLC (0.21%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Houte Hans Van, Gwenn Hansen, Christine Ring, Stefani Wolff and Pierre Beaurang. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND) and Delta Air Lines (DAL). This page (NASDAQ:NRIX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NRIX Stock Alerts